Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (HOWL) Revenue
Annual & quarterly revenue history · segment & region breakdown
HOWL · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsWerewolf Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -100.00% |
| 2024-12-31 | $0.00B | -$0.02B | -90.55% |
| 2023-12-31 | $0.02B | +$0.00B | +21.60% |
| 2022-12-31 | $0.02B | +$0.02B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Werewolf Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Werewolf Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Werewolf Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
HOWL revenue · 4 questionsHOWL's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Werewolf Therapeutics, Inc. SEC filings · GAAP · Werewolf Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026